Connect Biopharma Holdings Ltd

Connect Biopharma is a clinical-stage biotechnology company that develops antibody therapies for inflammatory respiratory diseases. The company focuses on developing its lead drug candidate, rademikibart, an antibody targeting interleukin-4 receptor alpha. Rademikibart is in clinical development for treating acute exacerbations of asthma and chronic obstructive pulmonary disease, as well as for chronic treatment of these pulmonary conditions and atopic dermatitis. Its potential end-users are patients who suffer from these respiratory and inflammatory skin disorders.

The company is based in San Diego, California. It does not own or operate manufacturing facilities, instead relying on third-party contract manufacturers for raw materials and supplies. Connect Biopharma partners with Simcere Pharmaceutical to develop and commercialize rademikibart in Greater China, while maintaining rights in other global markets. Clinical trials for its drug candidate have taken place across several countries, including the United States, Poland, Hungary, China, South Korea, Australia, and New Zealand.

Summary of the business section of Connect Biopharma's latest annual report, written by StockData.